SCHEMBL21991737

SCHEMBL21991737

O=C(Nc1ccc(F)c(Cl)c1)c1ccnc(N[S+]([O-])CC2CC2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.47
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
KCNQ3 O43525 1/20 0.45
KCNQ2 O43526 1/20 0.45
KCNE1 P15382 1/20 0.45
KCNQ1 P51787 1/20 0.45
MAOB P27338 3/20 0.44
MAOA P21397 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
MAPT P10636 3/20 0.43
GSK3B P49841 3/20 0.43
ALDH1A1 P00352 2/20 0.42
TSHR P16473 1/20 0.42
MAPK14 Q16539 1/20 0.42
MALT1 Q9UDY8 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21991038 0.95 ALDH1A1 (0.46) L3MBTL1NPC1RAB9ASMN1; SMN2KCNQ3
SCHEMBL21991156 0.89 GRM4 (0.42) L3MBTL1NPC1RAB9ASMN1; SMN2KCNQ3
SCHEMBL21990941 0.87 L3MBTL1 (0.47) L3MBTL1NPC1RAB9ASMN1; SMN2KCNQ3
SCHEMBL19380323 0.86 ALDH1A1 (0.46) L3MBTL1NPC1RAB9ASMN1; SMN2KCNQ3
SCHEMBL21991040 0.85 L3MBTL1 (0.45) L3MBTL1NPC1RAB9ASMN1; SMN2KCNQ3
SCHEMBL17880510 0.84 MAPK14 (0.58) L3MBTL1NPC1RAB9ASMN1; SMN2KCNQ3
SCHEMBL21991042 0.83 SMN1; SMN2 (0.47) L3MBTL1NPC1RAB9ASMN1; SMN2KCNQ3
SCHEMBL21990943 0.83 L3MBTL1 (0.46) L3MBTL1NPC1RAB9ASMN1; SMN2KCNQ3
SCHEMBL21990938 0.83 L3MBTL1 (0.46) L3MBTL1NPC1RAB9ASMN1; SMN2KCNQ3
SCHEMBL21991143 0.83 L3MBTL1 (0.46) L3MBTL1NPC1RAB9ASMN1; SMN2KCNQ3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3227262-B1 SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT NOVIRA THERAPEUTICS INC (US) 2020-05-13 EP disclosed